These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38919636)

  • 1. Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.
    Szafoni S; Gręblowski P; Grabowska K; Więckiewicz G
    Front Psychiatry; 2024; 15():1406888. PubMed ID: 38919636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.
    Ching THW; Grazioplene R; Bohner C; Kichuk SA; DePalmer G; D'Amico E; Eilbott J; Jankovsky A; Burke M; Hokanson J; Martins B; Witherow C; Patel P; Amoroso L; Schaer H; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1178529. PubMed ID: 37181888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At the Forefront: Social Workers' Role in Psilocybin Treatment for Depression and Substance Misuse.
    Parker C; Wood BM
    Soc Work; 2024 Jun; 69(3):297-302. PubMed ID: 38697188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.
    Andersen KAA; Carhart-Harris R; Nutt DJ; Erritzoe D
    Acta Psychiatr Scand; 2021 Feb; 143(2):101-118. PubMed ID: 33125716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing potential of psilocybin for depressive disorders.
    Kozak Z; Johnson MW; Aaronson ST
    Expert Opin Investig Drugs; 2023; 32(10):887-900. PubMed ID: 37869790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the clinical evidence on psilocybin for the treatment of psychiatric disorders? A systematic review.
    Castro Santos H; Gama Marques J
    Porto Biomed J; 2021; 6(1):e128. PubMed ID: 33884324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation.
    Modlin NL; Miller TM; Rucker JJ; Kirlic N; Lennard-Jones M; Schlosser D; Aaronson ST
    J Affect Disord; 2023 Apr; 326():18-25. PubMed ID: 36707036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psilocybin for treating substance use disorders?
    de Veen BT; Schellekens AF; Verheij MM; Homberg JR
    Expert Rev Neurother; 2017 Feb; 17(2):203-212. PubMed ID: 27684102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effect of psilocybin in addiction: A systematic review.
    van der Meer PB; Fuentes JJ; Kaptein AA; Schoones JW; de Waal MM; Goudriaan AE; Kramers K; Schellekens A; Somers M; Bossong MG; Batalla A
    Front Psychiatry; 2023; 14():1134454. PubMed ID: 36846225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
    Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; Curran VH; Nutt DJ
    Lancet Psychiatry; 2016 Jul; 3(7):619-27. PubMed ID: 27210031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.
    Ching THW; Amoroso L; Bohner C; D'Amico E; Eilbott J; Entezar T; Fitzpatrick M; Fram G; Grazioplene R; Hokanson J; Kichuk SA; Martins B; Patel P; Schaer H; Shnayder S; Witherow C; Pittenger C; Kelmendi B
    Front Psychiatry; 2023; 14():1278823. PubMed ID: 38264632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].
    Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J
    Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review.
    Sharma R; Batchelor R; Sin J
    J Psychoactive Drugs; 2023; 55(5):612-630. PubMed ID: 36933948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial.
    Husain MI; Blumberger DM; Castle DJ; Ledwos N; Fellows E; Jones BDM; Ortiz A; Kloiber S; Wang W; Rosenblat JD; Mulsant BH
    BJPsych Open; 2023 Jul; 9(4):e134. PubMed ID: 37489299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.